Petmed Express INC

PetMed Express, Inc. announced a definitive agreement for a sale-leaseback transaction of its headquarters and distribution center buildings for $37 million, aiming to unlock shareholder value and enhance financial flexibility.

PetMed Express, Inc. announced that director Leah A. Solivan will not stand for reelection at the 2026 annual meeting.

PetMed Express announced its fourth quarter and fiscal year 2026 financial results, reporting a decrease in net sales and a reduced net loss for the quarter, while the full year saw a significant increase in net loss.

PetMed Express announced its 2026 Annual Meeting will be held virtually on August 11, 2026, necessitating revised deadlines for shareholder proposals and director nominations.

PetMed Express, Inc. announced the successful election of its director nominees, advisory approval of executive compensation, and ratification of its independent auditor at its Annual Meeting of Shareholders on January 21, 2026.

PetMed Express, Inc. filed an amendment to clarify the effective date of its auditor dismissal and confirm no disagreements with the outgoing firm.

PetMed Express reported a significant net loss and revenue decline for the quarter and nine months ended December 31, 2025, alongside a financial restatement, goodwill impairment, and ongoing review of unsolicited acquisition proposals.

PetMed Express, Inc. reported a significant net loss and substantial revenue decline for the quarter and six months ended September 30, 2025, alongside a restatement of prior period financials and a $27.3 million impairment charge.

PetMed Express reports a significant net loss of $34.15 million for Q1 2026, driven by a $27.26 million goodwill and intangible asset impairment and a 22.7% drop in net sales.

PetMed Express reports a decrease in net sales for the quarter ended December 31, 2024, driven by a strategic reduction in advertising spend.

PetMed Express experienced a decrease in sales for the second quarter of fiscal year 2025, alongside a strategic reduction in marketing spend and a change in the definition of a new customer.

PetMed Express experienced a 13.2% decrease in sales for the quarter ended June 30, 2024, compared to the same period last year, alongside a net loss, and is addressing material weaknesses in internal controls.

PetMed Express, Inc. announced its annual report for the fiscal year ended March 31, 2026, detailing a substantial decrease in net sales and a significant increase in net loss, alongside ongoing efforts to remediate material weaknesses in internal controls.

PetMed Express, Inc. has filed a comprehensive annual report on Form 10-K, restating prior financial statements due to accounting errors and announcing significant leadership changes following an internal audit committee investigation.

PetMed Express, Inc.'s 2024 annual report reveals a year of strategic transitions, including the acquisition of PetCareRx, alongside financial headwinds and internal control weaknesses.

PetMed Express has restated its financial statements for fiscal years 2021 through 2023 due to accounting errors primarily related to sales tax liabilities.

Douglas Krulik, CAO and Interim CFO of Petmed Express Inc, reported multiple transactions in common stock on June 26, 2026.

Douglas Krulik, CAO and Interim CFO of PetMed Express, Inc., was granted restricted stock awards and performance share units on June 26, 2026.

Nina Capital Holdings Inc. acquired 25,000 shares of PetMed Express (PETS) at an average price of $1.749 per share.

PetMed Express director Gian Fulgoni has terminated his service, resulting in the forfeiture of 26,057 restricted shares.

PetMed Express director Gian Fulgoni received a restricted stock award of 33,846 common shares, vesting in October 2026.

PetMed Express, Inc. granted its CAO and Interim CFO, Douglas Krulik, 20,000 restricted common stock shares as part of its 2024 Omnibus Incentive Plan.

PetMed Express, Inc. has filed its 2026 Proxy Statement, outlining director elections, executive compensation, and a proposal to increase shares under its 2024 Omnibus Incentive Plan.

PetMed Express, Inc. announces its 2026 Annual Meeting of Shareholders to elect directors, approve executive compensation, and ratify a new independent auditor, Baker Tilly US, LLP, following the dismissal of RSM US LLP due to material weaknesses in internal controls.

PetMed Express files an amendment to its definitive proxy statement to correct information in the Pay versus Performance Table regarding Other NEOs' compensation for fiscal years 2022 and 2021.

PetMed Express, Inc. has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.

PetMed Express is asking shareholders to approve a new omnibus incentive plan to attract and retain key personnel.

SilverCape Investments Limited has submitted a revised non-binding proposal to acquire PetMed Express, Inc. for $3.00 per share in cash, representing a 70% premium over the recent closing price, citing the company's deteriorating financial condition and governance issues.

Diveroli Investment Group LLC and Kingbird Ventures LLC have disclosed a 1.83% beneficial ownership stake in PetMed Express, Inc., signaling potential future influence.

SilverCape Investments Limited has submitted a non-binding proposal to acquire all outstanding shares of PetMed Express Inc. for $4.00 per share in cash, aiming to take the company private.

SilverCape Investments Limited and its managing director Peter Kennedy have disclosed an 11.1% beneficial ownership stake in PetMed Express, Inc., signaling intent to engage with management on strategic decision-making and financial performance.

SilverCape Investments Limited has filed an amended Schedule 13G, reporting a 10.12% beneficial ownership stake in PetMed Express Inc.

SilverCape Investments Limited has filed a Schedule 13G, revealing a 5.00% beneficial ownership stake in PetMed Express Inc.'s common stock.

Hotchkis and Wiley Capital Management, LLC has filed an amended Schedule 13G, reporting a 4.7% beneficial ownership stake in PetMed Express Inc. as of December 31, 2024.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.66% beneficial ownership stake in PetMed Express Inc. as of December 31, 2024.